SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

News Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Delayed Hong Kong S.E. Other stock markets 03:39:30 21/05/2024 BST			5-day change	1st Jan Change
13.1 ^HKD	-3.25%		-2.24%	-22.94%

05-15	Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	MT
05-15	China Approves Clinical Trials For Breast Cancer Drugs	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	05-15	MT
China Approves Clinical Trials For Breast Cancer Drugs	05-15	MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	05-10	MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	05-09	MT
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	05-07	MT
Fosun Pharma's Q1 Profit Slumps 38%	04-30	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	04-24	MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	04-18	MT
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	04-17	MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-15	AQ
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	04-08	MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	04-02	CI
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	03-30	CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	03-27	MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	03-26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	03-26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	03-25	CI
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	03-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Summary

Filters